In Vivo E2F Reporting Reveals Efficacious Schedules of MEK1/2-CDK4/6 Targeting and mTOR-S6 Resistance Mechanisms

Cancer Discovery
Jessica L F TehAndrew E Aplin

Abstract

Targeting cyclin-dependent kinases 4/6 (CDK4/6) represents a therapeutic option in combination with BRAF inhibitor and/or MEK inhibitor (MEKi) in melanoma; however, continuous dosing elicits toxicities in patients. Using quantitative and temporal in vivo reporting, we show that continuous MEKi with intermittent CDK4/6 inhibitor (CDK4/6i) led to more complete tumor responses versus other combination schedules. Nevertheless, some tumors acquired resistance that was associated with enhanced phosphorylation of ribosomal S6 protein. These data were supported by phospho-S6 staining of melanoma biopsies from patients treated with CDK4/6i plus targeted inhibitors. Enhanced phospho-S6 in resistant tumors provided a therapeutic window for the mTORC1/2 inhibitor AZD2014. Mechanistically, upregulation or mutation of NRAS was associated with resistance in in vivo models and patient samples, respectively, and mutant NRAS was sufficient to enhance resistance. This study utilizes an in vivo reporter model to optimize schedules and supports targeting mTORC1/2 to overcome MEKi plus CDK4/6i resistance.Significance: Mutant BRAF and NRAS melanomas acquire resistance to combined MEK and CDK4/6 inhibition via upregulation of mTOR pathway signaling. T...Continue Reading

References

May 20, 2009·Bioinformatics·Heng Li, Richard Durbin
Jul 6, 2010·Nucleic Acids Research·Kai WangHakon Hakonarson
Feb 12, 2013·Nature Biotechnology·Kristian CibulskisGad Getz
Apr 2, 2013·The Journal of Clinical Investigation·Ethan V AbelAndrew E Aplin
Oct 4, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Karen E Sheppard, Grant A McArthur
Apr 4, 2014·Bioinformatics·Anthony M BolgerBjoern Usadel
Sep 16, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Elizabeth K ZiemkeJudith S Sebolt-Leopold
Dec 4, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Wenyue HuAida I Sacaan
Dec 15, 2015·Cancer Discovery·Charles J SherrGeoffrey I Shapiro
Jan 6, 2016·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Zhen TaoBo Lu
May 31, 2016·Molecular Cell·Jinfang ZhangWenyi Wei
Jun 9, 2016·Genome Biology·William McLarenFiona Cunningham
Dec 14, 2016·The New England Journal of Medicine·Richard S FinnDennis J Slamon
Apr 8, 2017·Cell·Robert A Saxton, David M Sabatini
Sep 20, 2017·Cancer Discovery·Aayoung HongRoger S Lo

❮ Previous
Next ❯

Citations

Nov 6, 2018·Endocrine-related Cancer·Neil PortmanC Elizabeth Caldon
Sep 5, 2020·The Oncologist·Alexandra Valeska MatterSimone M Goldinger
Aug 16, 2019·Science Translational Medicine·Anna E VilgelmAnn Richmond
May 3, 2020·Journal of Hematology & Oncology·Qi DuQin Li
Apr 11, 2020·Pigment Cell & Melanoma Research·Gretchen M Alicea, Vito W Rebecca
Jun 7, 2020·Nature Communications·Vito W RebeccaMeenhard Herlyn
May 3, 2018·Cancer Discovery·Ryan J Sullivan
Jul 15, 2020·Cancer Immunology Research·Jessica L F TehAndrew E Aplin
Mar 2, 2019·Cancer Research·Tikvah K HayesCory M Johannessen
May 21, 2020·Molecular Cancer Therapeutics·Jessica L F TehAndrew E Aplin
Aug 18, 2018·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Marcos Malumbres
Oct 6, 2018·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jessica L F Teh, Andrew E Aplin
Apr 15, 2020·Cancer Cell·Mónica Álvarez-Fernández, Marcos Malumbres
Aug 1, 2018·Trends in Cell Biology·Shom GoelJean J Zhao
Mar 25, 2021·Hematology/oncology Clinics of North America·Stephen M Ostrowski, David E Fisher
Jun 3, 2021·Cells·Mattia GaruttiFabio Puglisi
Jun 8, 2021·Cancer Treatment Reviews·Tijana RandicStephanie Kreis
Aug 12, 2021·Molecular Cancer Therapeutics·Kelsey W NassarRebecca E Schweppe
Jan 14, 2022·Science·Anne FasslPiotr Sicinski

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.